Almirall, S.A. and GW Pharmaceuticals plc today announced that the health authorities in Spain have granted regulatory approval for Sativex® Oromucosal Spray as an add-on therapy for the treatment of moderate to severe spasticity due to Multiple Sclerosis (MS) in patients who have not responded adequately to other anti-spasticity medication.
Prior to launch, Sativex® requires pricing and reimbursement approval from the Spanish Ministry of Health. This final approval process is expected to be completed during the 4th Quarter of 2010... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814